Novartis dominates Adakveo market as EU withdrawal reshapes outlook

Novartis AG held 100% of global Adakveo sales in 2024, according to The Business Research Company, underscoring how concentrated the sickle cell disease drug market has become. The outlook changed further after Novartis pulled Adakveo from EU and EEA markets in 2023 following a regulatory review tied to Phase III STAND study results.

Why it matters: - Adakveo’s market is tightly concentrated around one brand and one company, which makes regulatory decisions and clinical data especially important for access, revenue, and competition. - The EU withdrawal of Adakveo changed commercial availability in a major region and signaled how quickly evidence reviews can alter treatment adoption. - The market remains tied to broader demand for sickle cell disease therapies that reduce vaso-occlusive crises and improve long-term disease management.

What happened: - The Business Research Company said Novartis AG led global Adakveo sales in 2024 with a 100% market share. - Novartis AG was identified as the only major company operating in the Adakveo market. - In August 2023, Novartis announced the removal of Adakveo, also known as crizanlizumab, from European Union and European Economic Area markets. - The move followed a European Commission decision endorsing a CHMP recommendation to revoke Adakveo’s conditional marketing authorization.

The details: - The report describes the market as highly concentrated, with the top player accounting for all reported 2024 revenue. - The competitive setup reflects regulatory and commercialization barriers tied to biologic development, clinical validation, manufacturing, and distribution. - Novartis’s Adakveo portfolio is positioned as a targeted biologic treatment for sickle cell disease and vaso-occlusive crisis reduction. - The report lists major raw material suppliers including Thermo Fisher Scientific, Merck KGaA, Sartorius AG, Lonza Group, Danaher Corporation, Avantor Inc., Repligen Corporation, Wacker Chemie AG, FUJIFILM Irvine Scientific, AGC Biologics, Roquette Frères, Evonik Industries AG, DuPont, Corning Incorporated, Bio-Rad Laboratories, Eppendorf SE, 3M Company, Asahi Kasei Corporation, Charles River Laboratories International Inc., and Boehringer Ingelheim BioXcellence. - Major wholesalers and distributors listed in the report include McKesson Specialty Health, McKesson Plasma and Biologics, Cardinal Health, ASD Specialty Healthcare, Cencora, CVS Specialty, Accredo Health Group, Optum Specialty Pharmacy, BioCareSD, Onco360, CuraScript SD, Amerita Specialty Infusion, AllianceRx Walgreens Pharmacy, Shields Health Solutions, Kroger Specialty Pharmacy, Senderra Specialty Pharmacy, PANTHERx Rare Pharmacy, CarelonRx Specialty Pharmacy, FFF Enterprises Inc., and Morris & Dickson Co. LLC. - Major end users listed in the report include Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, St. Jude Children's Research Hospital, Memorial Sloan Kettering Cancer Center, Mount Sinai Health System, Duke University Health System, Vanderbilt University Medical Center, Yale New Haven Health, Stanford Health Care, Northwestern Memorial Hospital, Houston Methodist Hospital, UC Davis Health, Children's National Hospital, City of Hope, NYU Langone Health, Cedars-Sinai Medical Center, Montefiore Medical Center, Tampa General Hospital, and Massachusetts General Hospital. - The report says companies are emphasizing targeted biologic therapies, clinical evidence expansion, precision therapeutics, patient access initiatives, and research investments. - The report also says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and key technology and future trend analysis. - The report offers a free sample request and a detailed market report.

Between the lines: - The combination of 100% market share and a regional withdrawal suggests Adakveo’s competitive story is driven less by broad rivalry and more by regulatory status and clinical evidence. - The report’s supplier, distributor, and end-user lists point to a specialty-healthcare ecosystem rather than a mass-market pharmaceutical channel. - The Phase III STAND study is the key data point cited for the EU regulatory action, which means future positioning will likely depend on how evidence is interpreted by regulators and payers.

What's next: - Market access decisions, future clinical evidence, and regulatory reviews will shape whether Adakveo regains broader traction or remains constrained. - Novartis’s next moves in sickle cell disease treatment will likely focus on access, evidence generation, and portfolio strength in specialized hematology care. - Stakeholders watching the category will need to track whether new therapies or updated data change the current one-player market structure.

The bottom line: - Adakveo sits in a narrow, regulation-sensitive market where one company currently dominates and one safety-and-evidence decision can quickly reshape commercial prospects.